# GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

> **NCT04535713** · PHASE2 · RECRUITING · sponsor: **Sarcoma Oncology Research Center, LLC** · enrollment: 260 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Doxorubicin
- **DRUG:** Docetaxel
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04535713
- **Lead sponsor:** Sarcoma Oncology Research Center, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-30
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2024-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04535713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04535713, "GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04535713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*